Recombinant Anti-Tau (phospho T205) antibody [EPR23505-13] - BSA and Azide free (ab275027)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR23505-13] to Tau (phospho T205) - BSA and Azide free
- Suitable for: WB, IHC-Fr, Dot blot, IP, IHC-P
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Tau (phospho T205) antibody [EPR23505-13] - BSA and Azide free
See all Tau primary antibodies -
Description
Rabbit monoclonal [EPR23505-13] to Tau (phospho T205) - BSA and Azide free -
Host species
Rabbit -
Specificity
The specificity of this antibody refers to P10636-8.
-
Tested applications
Suitable for: WB, IHC-Fr, Dot blot, IP, IHC-Pmore details
Unsuitable for: ICC/IF -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human brain tissue lysate; Mouse brain tissue lysate; rat hippocampus tissue lysate. IHC-P: Human Alzheimer's disease cerebrum and breast tissue; Rat cerebrum tissue. IHC-Fr: Rat cerebrum tissue; Mouse cerebrum tissue. IP: Rat brain tissue lysate; Mouse brain tissue lysate.
-
General notes
ab275027 is the carrier-free version of ab254410.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Dissociation constant (KD)
KD = 1.00 x 10 -12 M Learn more about KD -
Storage buffer
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR23505-13 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Anti-Tau (phospho T205) antibody [EPR23505-13] (ab254410)
- Alexa Fluor® 555 Anti-Tau (phospho T205) antibody [EPR23505-13] (ab307334)
- Alexa Fluor® 647 Anti-Tau (phospho T205) antibody [EPR23505-13] (ab307376)
- Alexa Fluor® 488 Anti-Tau (phospho T205) antibody [EPR23505-13] (ab313824)
- Biotin Anti-Tau (phospho T205) antibody [EPR23505-13] (ab314404)
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab275027 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Detects a band of approximately 50-70 kDa (predicted molecular weight: 78 kDa).
|
|
IHC-Fr |
Use at an assay dependent concentration.
Heat mediated antigen retrieval using sodium citrate buffer (10mM citrate pH 6.0 + 0.05% Tween-20). |
|
Dot blot |
Use at an assay dependent concentration.
|
|
AP |
Use at an assay dependent concentration.
Antibody concentration range - 6.67, 3.33, 1.67, 0.83, 0.42, 0 nM/mL |
|
IP |
Use at an assay dependent concentration.
|
|
IHC-P |
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
Notes |
---|
WB
Use at an assay dependent concentration. Detects a band of approximately 50-70 kDa (predicted molecular weight: 78 kDa). |
IHC-Fr
Use at an assay dependent concentration. Heat mediated antigen retrieval using sodium citrate buffer (10mM citrate pH 6.0 + 0.05% Tween-20). |
Dot blot
Use at an assay dependent concentration. |
AP
Use at an assay dependent concentration. Antibody concentration range - 6.67, 3.33, 1.67, 0.83, 0.42, 0 nM/mL |
IP
Use at an assay dependent concentration. |
IHC-P
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Function
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. -
Tissue specificity
Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system. -
Involvement in disease
Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. -
Sequence similarities
Contains 4 Tau/MAP repeats. -
Developmental stage
Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain. -
Domain
The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats. -
Post-translational
modificationsPhosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD. -
Cellular localization
Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components. - Information by UniProt
-
Database links
- Entrez Gene: 4137 Human
- Entrez Gene: 17762 Mouse
- Entrez Gene: 29477 Rat
- Omim: 157140 Human
- SwissProt: P10636 Human
- SwissProt: P10637 Mouse
- SwissProt: P19332 Rat
- Unigene: 101174 Human
see all -
Form
There are 9 isoforms produced by alternative splicing. -
Alternative names
- AI413597 antibody
- AW045860 antibody
- DDPAC antibody
see all
Images
-
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Rat cerebrum tissue labeling Tau (phospho T205) with ab254410 at 1/20000 dilution followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on rat cerebrum without alkaline phosphatase treatment (image A, PMID: 28035925). No signal was detected when tissues were treated with alkaline phosphatase (image B).The section was incubated with ab254410 for 10 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 10 mins.
-
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of 4% PFA-fixed, 0.2% Triton X-100 permeabilized frozen Mouse cerebrum tissue labeling Tau (phospho T205) with ab254410 at 1/500 (1.034 ug/ml) dilution followed by ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution (Green). Positive staining on mouse cerebrum, while nearly no staining on mouse cerebrum after alkaline phosphatase (AP) treatment. The nuclear counterstain was DAPI (Blue).
Secondary antibody control: Secondary antibody is ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution.
Heat mediated antigen retrieval using sodium citrate buffer (10mM citrate pH 6.0 + 0.05% Tween-20).
-
All lanes : Anti-Tau (phospho T205) antibody [EPR23505-13] (ab254410) at 1/1000 dilution
Lane 1 : Human brain tissue lysate
Lane 2 : Human brain tissue lysate (phosphatase treated membrane)
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/100000 dilution
Predicted band size: 78 kDa
Observed band size: 50-70 kDa why is the actual band size different from the predicted?This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
The molecular weight observed is consistent with what has been described in the literature (PMID: 21722209).
-
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Dot blot analysis of Tau (phospho T205) labeled with ab254410 at 1/1000 dilution.
Lane 1: Tau (phospho S202+T205) peptide (aa 199-211).
Lane 2: Tau (phospho S202+T205) peptide (aa 197-209).
Lane 3: Tau peptide (aa 197-211).
Lane 4: Tau (phospho S202) peptide (aa 197-211).
Lane 5: Tau (phospho T205) peptide (aa 197-211).
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution was used as secondary antibody.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
-
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Tau (phospho T205) was immunoprecipitated from 0.35 mg Rat brain tissue lysate with ab254410 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab254410 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: Rat brain tissue lysate 10 ug
Lane 2: ab254410 IP in Rat brain tissue lysate
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab254410 in Rat brain tissue lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
-
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of 4% PFA-fixed, 0.2% Triton X-100 permeabilized frozen Rat cerebrum tissue labeling Tau (phospho T205) with ab254410 at 1/500 (1.034 ug/ml) dilution followed by ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/1000 dilution (Green). Positive staining on rat cerebrum, while nearly no staining on rat cerebrum after alkaline phosphatase (AP) treatment. The nuclear counterstain was DAPI (Blue).
Secondary antibody control: Secondary antibody is ab150077 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)at 1/1000 dilution.
Heat mediated antigen retrieval using sodium citrate buffer (10mM citrate pH 6.0 + 0.05% Tween-20).
-
All lanes : Anti-Tau (phospho T205) antibody [EPR23505-13] (ab254410) at 1/1000 dilution
Lane 1 : Rat hippocampus tissue lysate
Lane 2 : Rat hippocampus tissue lysate (phosphatase treated membrane)
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/100000 dilution
Predicted band size: 78 kDa
Observed band size: 50-70 kDa why is the actual band size different from the predicted?This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 48 seconds.
The molecular weight observed is consistent with what has been described in the literature (PMID: 21722209).
-
All lanes : Anti-Tau (phospho T205) antibody [EPR23505-13] (ab254410) at 1/1000 dilution
Lane 1 : Mouse brain tissue lysate
Lane 2 : Mouse brain tissue lysate (phosphatase treated membrane)
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/100000 dilution
Predicted band size: 78 kDa
Observed band size: 50-70 kDa why is the actual band size different from the predicted?This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 70 seconds.
The molecular weight observed is consistent with what has been described in the literature (PMID: 21722209).
-
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human breast tissue labeling Tau (phospho T205) with ab254410 at 1/20000 dilution followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on human breast without alkaline phosphatase treatment (image A, PMID: 15914550). No signal was detected when tissues were treated with alkaline phosphatase (image B). The section was incubated with ab254410 for 10 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 10 mins.
-
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Tau (phospho T205) was immunoprecipitated from 0.35 mg Mouse brain tissue lysate with ab254410 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab254410 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: Mouse brain tissue lysate 10 ug
Lane 2: ab254410 IP in Mouse brain tissue lysate
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab254410 in Mouse brain tissue lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 10 seconds.
-
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded Human Alzheimer's disease cerebrum tissue labeling Tau (phospho T205) with ab254410 at 1/20000 dilution followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on human Alzheimer's disease cerebrum without alkaline phosphatase treatment (image A, PMID: 20631843). No signal was detected when tissues were treated with alkaline phosphatase (image B). The section was incubated with ab254410 for 10 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 10 mins.
-
Biotinylated Tau (phospho T205) peptide [0.1 µg/ml] was loaded to SA biosensor on Fortebio RED96e Machine, then associate with recombinant Anti-Tau (phospho T205) antibody [EPR23505-13] in serial concentration points [6.67, 3.33, 1.67, 0.83, 0.42 nM/mL] by 2-fold dilution, next to dissociate in blank testing buffer [0.1% BSA in PBST (0.05%Tween-20)]. Calculated signals had already subtracted blank control, curve fitting using 1:1 binding model. Non-phospho Tau peptide’ association and dissociation were also showed in graph. KD(M) value of Anti-Tau (phospho T205) antibody [EPR23505-13] is <1.0E-12
This data was developed using ab254410, the same antibody clone in a different buffer formulation.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (0)
ab275027 has not yet been referenced specifically in any publications.